Phenotypes Associated with This Genotype

Genotype
MGI:5558023

• Allelic Composition: Sirpa^tm1Umri/Sirpa^tm1Umri; Tg(CAG-cre/Esr1*)1Lbe/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

abnormal synapse morphology ( J:204011 )

• as determined by VGLUT1 (Slc17a7) staining, mice treated with tamoxifen at P15 exhibit impaired maturation of presynaptic terminals compared with control mice

• however, mice treated tamoxifen at P0 exhibit normal initial synapse development and mice treated at P30 exhibit normal synapse maintenance

abnormal synaptic vesicle morphology ( J:204011 )

• irregular shape in tamoxifen-treated mice

abnormal synaptic vesicle number ( J:204011 )

• tamoxifen treated mice exhibit fewer synaptic vesicles and fewer docked synaptic vesicles in asymmetric synapses compared with control mice

abnormal excitatory postsynaptic potential ( J:204011 )

• strongly diminished Input-output curves of field excitatory postsynaptic potential slope in tamoxifen-treated mice

• however, fiber volley amplitude is normal

reduced long-term potentiation ( J:204011 )

• in tamoxifen-treated mice

enhanced paired-pulse facilitation ( J:204011 )

• in tamoxifen-treated mice

cellular

abnormal synaptic vesicle morphology ( J:204011 )

• irregular shape in tamoxifen-treated mice

abnormal synaptic vesicle number ( J:204011 )

• tamoxifen treated mice exhibit fewer synaptic vesicles and fewer docked synaptic vesicles in asymmetric synapses compared with control mice